Camptothecins: from bench research to hospital wards.

[1]  G. Weiss,et al.  Phase I and pharmacokinetic trial of weekly CPT-11. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[3]  L. Moore,et al.  Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. , 1993, Journal of medicinal chemistry.

[4]  J. Supko,et al.  Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. , 1993, Cancer research.

[5]  A. Marchetti,et al.  p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. , 1993, Cancer research.

[6]  T. Taguchi,et al.  Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Arceci.  Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments] , 1993 .

[8]  S. Korsmeyer,et al.  Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. , 1993, Cancer research.

[9]  L. Zwelling,et al.  Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia , 1993 .

[10]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[11]  M. Fukuoka,et al.  CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Saijo,et al.  Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.

[13]  T. Burke,et al.  Liposomal stabilization of camptothecin's lactone ring , 1992 .

[14]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[15]  H. Ohmatsu,et al.  Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. , 1992, Journal of the National Cancer Institute.

[16]  L. Grochow,et al.  Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.

[17]  Y. Pommier,et al.  Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. , 1992, European journal of cancer.

[18]  Y. Miura,et al.  Effects of CPT‐11 in combination with other anti‐cancer agents in culture , 1992, International journal of cancer.

[19]  C. Yu,et al.  Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. , 1991, Cancer research.

[20]  G. Hofmann,et al.  Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). , 1991, Cancer research.

[21]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[22]  B. Giovanella,et al.  Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. , 1991, Cancer research.

[23]  J. Wang,et al.  DNA topoisomerases: why so many? , 1991, The Journal of biological chemistry.

[24]  S. Kaufmann,et al.  Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. , 1991, Cancer research.

[25]  M. Shibuya,et al.  Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. , 1991, British Journal of Cancer.

[26]  H. Mewes,et al.  p53 in colorectal cancer: clinicopathological correlation and prognostic significance , 1991, British Journal of Cancer.

[27]  Eric Patterson,et al.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites , 1991, Nucleic Acids Res..

[28]  R. Ohno,et al.  An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[30]  L. Liu,et al.  Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. , 1990, Cancer research.

[31]  T. Furuta,et al.  Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. , 1990, Cancer research.

[32]  M. Mattern,et al.  Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. , 1989, Journal of the National Cancer Institute.

[33]  J. Champoux,et al.  The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. , 1989, Nucleic acids research.

[34]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[35]  S. Kaufmann.  Additional members of the rat liver lamin polypeptide family. Structural and immunological characterization. , 1989, The Journal of biological chemistry.

[36]  R. Hertzberg,et al.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. , 1989, Biochemistry.

[37]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[38]  R. Hertzberg,et al.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. , 1989, Journal of medicinal chemistry.

[39]  J. Wang,et al.  Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Wang,et al.  DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Traganos,et al.  Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. , 1988, Cancer research.

[42]  W. Earnshaw,et al.  cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[44]  G. Manikumar,et al.  Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. , 1987, Journal of medicinal chemistry.

[45]  J. Wang,et al.  Supercoiling of the DNA template during transcription. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Wani,et al.  Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. , 1986, Journal of medicinal chemistry.

[48]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[49]  M. Duguet,et al.  DNA topoisomerases from rat liver: physiological variations. , 1983, Nucleic acids research.

[50]  G. Cordell,et al.  Plant Anticancer Agents XXI. Constituents of Merrilliodendron megacarpum* , 1981, Planta medica.

[51]  M. Wani,et al.  Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. , 1980, Journal of medicinal chemistry.

[52]  G. Cordell,et al.  Plant anticancer agents X. Isolation of camptothecin and 9-methoxycamptothecin from Ervatamia heyneana. , 1979, Journal of natural products.

[53]  L. Li,et al.  Action of camptothecin on mammalian cells in culture. , 1972, Cancer research.

[54]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[55]  S. Penman,et al.  Selective interruption of high molecular weight RNA synthesis in HeLa cells by camptothecin. , 1972, Nature: New biology.

[56]  D. Kessel,et al.  Camptothecin effects on DNA synthesis in murine leukemia cells. , 1972, Biochimica et biophysica acta.

[57]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[58]  Gottlieb Ja,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972 .

[59]  M. Horwitz,et al.  Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. , 1971, Biochemical and biophysical research communications.

[60]  A. Grollman,et al.  Studies on camptothecin. I. Effects of nucleic acid and protein synthesis. , 1971, Molecular pharmacology.

[61]  D. Kessel,et al.  Effects of camptothecin on RNA synthesis in leukemia L1210 cells. , 1971, Biochimica et biophysica acta.

[62]  H. Bosmann,et al.  Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria of E. coli. , 1970, Biochemical and biophysical research communications.

[63]  A. Guarino,et al.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.

[64]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[65]  L. Liu,et al.  Mechanisms of resistance to topoisomerase inhibitors. , 1994, Cancer treatment and research.

[66]  P. Hérait,et al.  High dose intensity of CPT-11 administered as single dose every 3 weeks: The instittut gustave roussy experience , 1993 .

[67]  S. Kim,et al.  Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. , 1992, International journal of radiation oncology, biology, physics.

[68]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Borst.  Genetic mechanisms of drug resistance. A review. , 1991, Acta oncologica.

[70]  T. Taguchi,et al.  [Phase I clinical study of CPT-11. Research group of CPT-11]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[71]  T. Tsuruo,et al.  Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue , 1990 .

[72]  S. Howell,et al.  Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. , 1990, European journal of cancer.

[73]  L. Liu,et al.  A model for tumor cell killing by topoisomerase poisons. , 1990, Cancer cells.

[74]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[75]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Champoux,et al.  Studies on the regulation and specificity of the DNA-untwisting enzyme. , 1979, Cold Spring Harbor symposia on quantitative biology.

[77]  S. Danishefsky,et al.  Synthesis and biological activity in the camptothecin series , 1973 .